Search Results - "Muxí, A"

COVID-19 vaccination unveiling subclinical Sjögren's syndrome by Ramos-Casals, Manuel, Sainz-de-la-Maza, Maite, Muxí, Africa

Get more information

Monitoring system for isolated limb perfusion based on a portable gamma camera by Orero, A, Vidal-Sicart, S, Roé, N, Muxí, A, Rubí, S, Duch, J, Rull, R, Pavón, N, Pons, F, Pavía, J

“…The treatment of malignant melanoma or sarcomas on a limb using extremity perfusion with tumour necrosis factor (TNF-alpha) and melphalan can result in a high…”
Get more information

Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury by Gifre, L., Vidal, J., Carrasco, J. L., Muxi, A., Portell, E., Monegal, A., Guañabens, N., Peris, P.

“…Summary Osteoporosis is a frequent complication related to spinal cord injury (SCI), and data on osteoporosis treatment after SCI is scarce. Treatment with…”
Get full text

Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study by Gifre, L., Vidal, J., Carrasco, J. L., Muxi, A., Portell, E., Monegal, A., Guañabens, N., Peris, P.

“…Summary Spinal cord injury (SCI) has been associated with a marked bone loss after injury and a consequent increased risk of osteoporosis. The evaluation of…”
Get full text

Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy by Gifre, L., Ruiz-Gaspà, S., Carrasco, J. L., Portell, E., Vidal, J., Muxi, A., Monegal, A., Guañabens, N., Peris, P.

“…Summary There is marked bone loss after spinal cord injury (SCI); however, its pathogenesis and clinical management remain unclear. The increased circulating…”
Get full text

Unveiling the speciality future: challenges and opportunities in nuclear medicine by Garcia, J.R., Jover, R., Mila, M., Muxi, A., Vallejos, V., Garcia, A., Caballero, E.

Get full text

Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant by Torregrosa, J.-V, Fuster, D, Monegal, A, Gentil, M. Á, Bravo, J, Guirado, L, Muxí, A, Cubero, J

“…Summary This study evaluates the efficacy of low doses of pamidronate after renal transplantation to prevent bone loss in osteopenic patients. Results show…”
Get full text

Analysis of the evolution of cortical and trabecular bone compartments in the proximal femur after spinal cord injury by 3D-DXA by Gifre, L., Humbert, L., Muxi, A., Del Rio, L., Vidal, J., Portell, E., Monegal, A., Guañabens, N., Peris, P.

“…Summary Marked trabecular and cortical bone loss was observed at the proximal femur short-term after spinal cord injury (SCI). 3D-DXA provided measurement of…”
Get full text

Patients with cirrhosis and ascites have false values of bone density: Implications for the diagnosis of osteoporosis by Guañabens, N., Monegal, A., Muxi, A., Martinez-Ferrer, A., Reyes, R., Caballería, J., Del Río, L., Peris, P., Pons, F., Parés, A.

“…Summary The effect of ascites on bone densitometry has been assessed in 25 patients with advanced cirrhosis, and it was concluded that ascites over 4 l causes…”
Get full text

123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease by Navarro-Otano, J., Gaig, C., Muxi, A., Lomeña, F., Compta, Y., Buongiorno, M.T., Martí, M.J., Tolosa, E., Valldeoriola, F.

“…Vascular parkinsonism (VP) may occur as a distinct clinicopathological entity but the comorbid presence of vascular damage in Parkinson's disease (PD) is very…”
Get full text

Bone metabolism disorders in patients awaiting liver transplantation. Has the situation improved in the last decade? by Monegal, A, Navasa, M, Peris, P, Colmenero, J, Muxi, A, Gifre, L, Guañabens, N

Get full text

Increased serum PTH levels in postmenopausal women with osteoporosis. Prevalence and clinical characteristics by Cerdà, D, Peris, P, Monegal, A, Albaladejo, C, Martínez, M, Muxí, Á, de Osaba, M.Martínez, Surís, X, Guañabens, N

Get full text

Aetiology and clinical characteristics of male osteoporosis. Have they changed in the last few years? by PERIS, P, MARTIEZ-FERRER, A, MONEGAL, A, MARTINEZ DE OSABA, M. J, ALVAREZ, L, ROS, I, MUXI, A, REYES, R, GUANABENS, N

“…The aim of this study was to analyse the clinical characteristics and etiological factors related to male osteoporosis in patients attending an out-patient…”
Get full text

Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: similar efficacy but different adherence by Guañabens, N, Cerdá, D, Monegal, A, Muxi, A, Caballeria, L, Peris, P, Pons, F, Pares, A

Get full text

Patients with ascites have false values of bone mineral density at the central skeleton. A prospective study by Guañabens, N, Martinez-Ferrer, A, Reyes, R, Monegal, A, Muxi, A, Caballeria, J, Peris, P, Pons, F, Pares, A

Get full text

Efecto del tratamiento con denosumab durante 24 meses en individuos con lesión medular reciente con osteoporosis by Gifre, L, Vidal, J, Carrasco, JL, Muxi, A, Portell, E, Monegal, A, Guañabens, N, Peris, P

“…Resumen Introducción: El desarrollo de osteoporosis es una complicación frecuente tras una lesión medular (LM), especialmente bajo el nivel de la lesión. Sin…”
Get full text

849 PATIENTS WITH ASCITES HAVE FALSE VALUES OF BONE MINERAL DENSITY AT THE CENTRAL SKELETON. A PROSPECTIVE STUDY by Martinez-Ferrer, A, Reyes, R, Monegal, A, Muxi, A, Caballeria, J, Peris, P, Pons, F, Parés, A, Guañnabens, N

Get full text

184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE by Parés, A, Cerdá, D, Monegal, A, Muxi, A, Caballeria, L, Peris, P, Pons, F, Guañnabens, N

Get full text

Dynamic model of the left ventricle for use in simulation of myocardial perfusion SPECT and gated SPECT by Bullich, S., Ros, D., Cot, A., Falcón, C., Muxı́, A., Pavia, J.

“…Simulation is a useful tool in cardiac SPECT to assess quantification algorithms. However, simple equation-based models are limited in their ability to…”
Get full text

Factores relacionados con la respuesta inadecuada al tratamiento osteoformador (teriparatida/PTH 1-84) en pacientes con osteoporosis severa: resultados preliminares by Gifre, L., Monegal, A., Filella, X., Muxi, A., Guañabens, N., Peris, P.

“…El objetivo de este estudio ha sido analizar la evolución de la masa ósea a largo plazo tras tratamiento osteoformador (teriparatida o PTH 1-84) en pacientes…”
Get full text